NanO2TM

Phase 2Small molecule

NNHS Greater Glasgow and Clyde

NanO2TM is one of 94 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeNot yet recruiting

Glioblastoma MultiformeActive, not recruiting

StrokePhase 2

Not yet recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

147 competitors in Stroke

#DrugCompanyPhaseTrials

Zometa

Pfizer

Preclinical

1 2

Savella

AbbVie

Preclinical

1 3

Proamatine

Repatha

NanO2TM

NNHS Greater Glasgow and Clyde

Phase 2

1 6

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Glioblastoma Multiforme

NCT03862430

Clinical

Trials by Indication[1]

Stroke1 trial

NanO2 in Large VessEL Occlusion Stroke (NOVEL)

Not yet recruiting·NNHS Greater Glasgow and Clyde·Phase 2·NCT06821347·172 enrolled

Glioblastoma Multiforme1 trial

A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE

Active, not recruiting·NNuvOx LLC·Phase 2·NCT03862430·87 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NanO2TM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NanO2TM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NanO2TM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NHS Greater Glasgow and Clyde company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNHS Greater Glasgow and Clyde

NanO2TM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Stroke1 trial

Glioblastoma Multiforme1 trial

References

Drug Info

Quick Facts

Related News